日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study

环孢素单药治疗无需输血的非重型再生障碍性贫血的疗效:一项多中心 II 期研究的结果

Ishiyama, Ken; Yamazaki, Masahide; Maruyama, Hiroyuki; Hosono, Naoko; Yamaguchi, Hiroki; Asada, Noboru; Tanimoto, Kazuki; Sugiura, Hiroyuki; Usuki, Kensuke; Yoshimura, Kenichi; Ogawa, Seishi; Kanakura, Yuzuru; Matsumura, Itaru; Akashi, Koichi; Nakao, Shinji

Prevention and Management of Thromboembolism in Patients with Paroxysmal Nocturnal Hemoglobinuria in Asia: A Narrative Review

亚洲阵发性睡眠性血红蛋白尿患者血栓栓塞的预防和管理:叙述性综述

Ueda, Yasutaka; Chou, Wen-Chien; Goh, Yeow-Tee; Rojnuckarin, Ponlapat; Kim, Jin Seok; Wong, Raymond Siu Ming; Lee Wong, Lily Lee; Jang, Jun Ho; Chiou, Tzeon-Jye; Kanakura, Yuzuru; Lee, Jong Wook

Treatment burden in patients with paroxysmal nocturnal hemoglobinuria: an in-depth interview survey

阵发性睡眠性血红蛋白尿患者的治疗负担:一项深入访谈调查

Ueda, Yasutaka; Obara, Naoshi; Ueno, Shikiko; Sakurai, Masatoshi; Hosokawa, Kohei; Murata, Tatsunori; Fukuoka, Yuta; Hayama, Nozomi; Yamashita, Masami; Ogawa, Yoshiaki; Usuki, Kensuke; Ikezoe, Takayuki; Kawaguchi, Tatsuya; Hosen, Naoki; Kanakura, Yuzuru; Gotoh, Akihiko; Nishimura, Jun-Ichi

Monitoring and Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia in Asia: An Expert Consensus

亚洲再生障碍性贫血患者阵发性睡眠性血红蛋白尿的监测与治疗:专家共识

Wong, Raymond Siu Ming; Ho Jang, Jun; Wong, Lily Lee Lee; Kim, Jin Seok; Rojnuckarin, Ponlapat; Goh, Yeow-Tee; Ueda, Yasutaka; Chou, Wen-Chien; Lee, Jong Wook; Kanakura, Yuzuru; Chiou, Tzeon-Jye

Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor BCR-ABL (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

开发和评估用于费城染色体阳性急性淋巴细胞白血病(Ph+ ALL)中次要BCR-ABL(e1a2)检测的快速一步高灵敏度实时定量PCR系统

Hidaka, Michihiro; Inokuchi, Koiti; Uoshima, Nobuhiko; Takahashi, Naoto; Yoshida, Nao; Ota, Shuichi; Nakamae, Hirohisa; Iwasaki, Hiromi; Watanabe, Kenichiro; Kosaka, Yoshiyuki; Komatsu, Norio; Meguro, Kuniaki; Najima, Yuho; Eto, Tetsuya; Kondo, Takeshi; Kimura, Shinya; Yoshida, Chikashi; Ishikawa, Yuichi; Sawa, Masashi; Hata, Tomoko; Horibe, Keizo; Iida, Hiroatsu; Shimomura, Takeshi; Dobashi, Nobuaki; Sugiura, Isamu; Makiyama, Junya; Miyagawa, Naoyuki; Sato, Asuka; Ito, Ryuta; Matsumura, Itaru; Kanakura, Yuzuru; Naoe, Tomoki

RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS

RGMa 破坏了神经元肌动蛋白屏障,阻碍了与疾病有关的蛋白质发挥作用,并加剧了 ALS

Mikito Shimizu, Naoyuki Shiraishi, Satoru Tada, Tsutomu Sasaki, Goichi Beck, Seiichi Nagano, Makoto Kinoshita, Hisae Sumi, Tomoyuki Sugimoto, Yoko Ishida, Toru Koda, Teruyuki Ishikura, Yasuko Sugiyama, Keigo Kihara, Minami Kanakura, Tsuneo Nakajima, Shuko Takeda, Masanori P Takahashi, Toshihide Yama

Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma

莫苏妥珠单抗单药治疗复发/难治性B细胞非霍奇金淋巴瘤日本患者的I期研究的剂量递增部分

Munakata, Wataru; Izutsu, Koji; Mishima, Yuko; Nagai, Hirokazu; Ishihara, Yuko; Suzumiya, Junji; Kanakura, Yuzuru; Nanki, Toshihiro; Miyake, Takeshi; Kawasaki, Atsuko; Yoshinaga, Tatsuya; Ishizawa, Kenichi

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria

Tesidolumab (LFG316) 用于治疗伴有阵发性睡眠性血红蛋白尿的 C5 变异型患者

Nishimura, Jun-Ichi; Ando, Kiyoshi; Masuko, Masayoshi; Noji, Hideyoshi; Ito, Yoshikazu; Mayer, Jiri; Griskevicius, Laimonas; Bucher, Christoph; Müllershausen, Florian; Gergely, Peter; Rozenberg, Izabela; Schubart, Anna; Chawla, Raghav; Rondeau, Jean-Michel; Roguska, Michael; Splawski, Igor; Keating, Mark T; Johnson, Leslie; Danekula, Rambabu; Bagger, Morten; Watanabe, Yoko; Haraldsson, Börje; Kanakura, Yuzuru

Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis

卡非佐米-来那度胺-地塞米松和卡非佐米-地塞米松治疗复发/难治性多发性骨髓瘤的真实世界疗效和安全性分析:一项多中心回顾性分析

Onda, Yoshiyuki; Kanda, Junya; Kaneko, Hitomi; Shimura, Yuji; Fuchida, Shin-Ichi; Nakaya, Aya; Itou, Tomoki; Yamamura, Ryosuke; Tanaka, Hirokazu; Shibayama, Hirohiko; Shimazu, Yutaka; Uchiyama, Hitoji; Yoshihara, Satoshi; Adachi, Yoko; Matsuda, Mitsuhiro; Hanamoto, Hitoshi; Uoshima, Nobuhiko; Kosugi, Satoru; Ohta, Kensuke; Yagi, Hideo; Kanakura, Yuzuru; Matsumura, Itaru; Hino, Masayuki; Nomura, Shosaku; Shimazaki, Chihiro; Takaori-Kondo, Akifumi; Kuroda, Junya

ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial

ASXL1 突变与血清 EPO 水平升高预示低危 MDS 患者对达贝泊汀α治疗反应不良:W-JHS MDS01 试验

Morita, Yasuyoshi; Nannya, Yasuhito; Ichikawa, Motoshi; Hanamoto, Hitoshi; Shibayama, Hirohiko; Maeda, Yoshinobu; Hata, Tomoko; Miyamoto, Toshihiro; Kawabata, Hiroshi; Takeuchi, Kazuto; Tanaka, Hiroko; Kishimoto, Junji; Miyano, Satoru; Matsumura, Itaru; Ogawa, Seishi; Akashi, Koichi; Kanakura, Yuzuru; Mitani, Kinuko